~~<i id='325051B91F'><strike id='325051B91F'><tt id='325051B91F'><pre id='325051B91F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：focus 2025-09-05 06:07:13 - browse：384

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Melinda French Gates resigns from Gates Foundation

focus

entertainment

leisure time

explore

Wikipedia

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Dogs on Prozac: What pet anti

Community Health Systems hospitals under DOJ investigation

PBM reform efforts get punted in Congress

He's a Nobel laureate. Critics say he was misleading on Covid

Cell therapy fails to slow type 1 diabetes, but safety is established

hotspot

comprehensive

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Obesity drugs seen as possible treatment for liver disease MASH

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A new nitrogen execution bill also undermines medical licensing

Anesthesiologist group: stop taking Ozempic before surgery

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Hollywood unions extend contract negotiations for actors

Alabama frozen embryo ruling has major implications for IVF clinics

How to save PrEP access — and even expand it

Why rehabilitation engineers need to center patients in their research

entertainment

Key Senate committee drafts bipartisan bill to stem drug shortages

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Why palliative psychiatry is worth discussing

FTC falls short on scrutinizing hospital mergers, study says

Q&A: Jennifer Adair on making gene therapy available globally

Exact Sciences stock tumbles despite strong cancer detection sales

entertainment

leisure time

explore

Wikipedia